- Home
- TACT vs VERU Comparison
TACT vs VERU Comparison
Compare TACT & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TACT
- VERU
- Stock Information
- Founded
- TACT 1996
- VERU 1971
- Country
- TACT United States
- VERU United States
- Employees
- TACT N/A
- VERU N/A
- Industry
- TACT Computer peripheral equipment
- VERU Biotechnology: Pharmaceutical Preparations
- Sector
- TACT Technology
- VERU Health Care
- Exchange
- TACT Nasdaq
- VERU Nasdaq
- Market Cap
- TACT 51.0M
- VERU 54.6M
- IPO Year
- TACT 1996
- VERU 1990
- Fundamental
- Price
- TACT $4.66
- VERU $4.29
- Analyst Decision
- TACT Strong Buy
- VERU Strong Buy
- Analyst Count
- TACT 1
- VERU 3
- Target Price
- TACT $5.00
- VERU $33.33
- AVG Volume (30 Days)
- TACT 51.9K
- VERU 173.0K
- Earning Date
- TACT 11-06-2025
- VERU 08-12-2025
- Dividend Yield
- TACT N/A
- VERU N/A
- EPS Growth
- TACT N/A
- VERU N/A
- EPS
- TACT N/A
- VERU N/A
- Revenue
- TACT $47,949,000.00
- VERU $16,886,419.00
- Revenue This Year
- TACT $21.67
- VERU N/A
- Revenue Next Year
- TACT $7.63
- VERU N/A
- P/E Ratio
- TACT N/A
- VERU N/A
- Revenue Growth
- TACT N/A
- VERU 337.24
- 52 Week Low
- TACT $3.12
- VERU $2.64
- 52 Week High
- TACT $5.70
- VERU $14.20
- Technical
- Relative Strength Index (RSI)
- TACT 40.08
- VERU 62.67
- Support Level
- TACT $4.53
- VERU $4.01
- Resistance Level
- TACT $5.26
- VERU $4.54
- Average True Range (ATR)
- TACT 0.34
- VERU 0.30
- MACD
- TACT -0.12
- VERU -0.03
- Stochastic Oscillator
- TACT 9.39
- VERU 66.67
About TACT TransAct Technologies Incorporated
Transact Technologies Inc develops and sells software-driven technology and printing solutions. The company's software is sold under BOHA, AccuDate, Epic, EPICENTRAL, Ithaca, and Printrex brand names. It also provides supplies and consumables used in the printing and scanning activities to restaurant and hospitality, banking, retail, casino and gaming, point of sale automation, lottery, medical, mobile, oil, and gas markets. Majority of the revenue is derived from the casinos and gaming industry followed by the Foodservice technology market. Its geographical segments are the United States and International, of which the majority of its revenue comes from the United States.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.